Loss of CDKN2A (encoding p16ink4a) expression, from methylation-induced CDKN2A promoter silencing, or mutations, is one alteration frequently observed in human breast cancers and cultured HMEC [6,13,14]. Here, CDKN2A is linked to breast carcinoma.